Abstract: |
Barrett's esophagus is recognized clearly to possess potential for neoplastic progression that can be identified endoscopically and confirmed by histologic evaluation. A diagnosis of dysplasia in Barrett's esophagus has major clinical and therapeutic consequences, although numerous studies have demonstrated that it is not completely reproducible. To ensure patient safety, it is imperative to establish a clear communication structure between individual team members who are involved in the management of Barrett's esophagus. Several nonmorphologic markers that have been proposed to complement the valuation reflect recent advances in the genetic and molecular processes that are involved in the carcinogenesis of Barrett's esophagus. The best ancillary tools are immunohistochemistry with antibodies directed against specific biomarkers, flow cytometry to assess gross DNA abnormalities, and fluorescence in situ hybridization for the detection of chromosomal aberrations. It is probable that in the near future techniques, such as global gene expression profiling with cDNA microarrays, identification of polymorphic genetic markers using single nucleotide polymorphic allele analysis, and proteomics, may increase the ability of pathologists to define and predict the malignant potential of different types of dysplasia and advance this field. © 2006 Elsevier Inc. All rights reserved. |